CPhI Online

- Biopharma News

Samsung Biologics to provide 'streamlining' services for KAHR Medical's cancer immunotherapy candidate

8 Jun 2021

The CDMO will also provide IND filling support for KAHR's drug candidate DSP502

Samsung Biologics has signed a deal with cancer immunotherapy company KAHR Medical in which the South Korean CDMO will provide end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as Investigational New Drug filling support for KAHR’s drug candidate DSP502.

KAHR Medical's novel multifunctional immuno-recruitment protein (MIRP) technology is a versatile immuno-therapeutic drug platform for multiple cancer types. The technology binds cancer cells and T-cells to produce a synergistic effect to selectively target tumours.

Two months ago, KAHR Medical signed an exclusive licence with Thomas Jefferson University in Philadelphia, PA to develop and commercialize multiple new drug candidates, including DSP502.

John Rim, CEO of Samsung Biologics, said they intend to "enable a faster transition from gene to IND to ensure KAHR’s success in bringing cutting edge immuno-recruitment cancer drugs to patients in need”.

The CDMO claims its CDO business can deliver cell line development to drug substance manufacturing in six months, and to drug product in sven months - the "fastest pace in the industry".

Read More

Related Content